News Column

ALNYLAM PHARMACEUTICALS, INC. FILES (8-K) Disclosing Change in Directors or Principal Officers

July 2, 2014



Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 1, 2014, the Board of Directors (the "Board") of Alnylam Pharmaceuticals, Inc. (the "Company") elected Amy W. Schulman as a Class III director with a term expiring at the annual meeting of stockholders to be held in 2016.

In connection with her election to the Board, Ms. Schulman received a stock option to purchase 30,000 shares of common stock of the Company, vesting annually over three years, and will be compensated as a director pursuant to the Company's compensation policy for non-employee directors, which is described in the Company's Proxy Statement for the 2014 Annual Meeting of Stockholders filed with the Securities and Exchange Commission on April 29, 2014.

--------------------------------------------------------------------------------


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Edgar Glimpses


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters